Companies / VRTX vs BMY
VRTX vs BMY: Vertex Pharmaceuticals and Bristol Myers Squibb
Vertex Pharmaceuticals (VRTX) reported $12.0B in revenue against a 32.9% net margin, while Bristol Myers Squibb (BMY) reported $48.2B at a 14.6% net margin, most recently.
| Metric | VRTX | BMY |
|---|---|---|
| Revenue | $12.0B | $48.2B |
| Net Income | $4.0B | $7.1B |
| Gross Margin | 86.2% | 71.1% |
| Operating Margin | 34.8% | 19.4% |
| EPS (Diluted) | $15.32 | $3.46 |
| Free Cash Flow | $3.2B | $12.8B |
| Total Debt | — | $47.1B |
| P/E Ratio | 29.6× | 15.6× |
| P/B Ratio | 6.2× | n/m |
| Stock Price | $542.69 | $63.16 |
Free: last 5 years
| Fiscal year | FY2008 🔒 | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VRTX Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| BMY Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |